Flyuorestsentnaya diagnostika predraka i nachal'nogo raka endometriya

The results of fluorescence diagnosis using Alasens (3% solution, 10 ml into the uterine cavity) in 120 patients were analyzed. Group 1 consisted of 80 women admitted for primary examination for the diagnosis to be morphologically verified. Group 2 included 40 reproductive age patients previously diagnosed as having atypical endometrial hyperplasia and early cancer of the corpus uteri, in whom fluorescence diagnosis was made as monitoring of individual hormone therapy. Alasens exposure lasted 2 hours. By comparing the data of spectral fluorescence and morphological studies, in Group 1 the authors diagnosed atypical endometrial hyperplasia in 19 (23.8%) women, early cancer of the corpus uteri (cr in situ, stage Ia) in 46 (57.5%), and a benign process (glandular endometrial hyperplasia, polyps of the corpus uteri) in 15 (18.8%). In Group 2, disease recurrence was found in 6 (15%) women after hormonal therapy.

Alasens, fluorescence diagnosis, spectrofluorometry, endometrial precancer, endometrial cancer